MU fell 12% on the week to close at $935.89, yet the most revealing detail is not the decline itself — it is that Goldman Sachs raised its price target to $900 on Tuesday, a day when the stock was already trading above that level and the most recent session had it lower still.
The analyst picture has become genuinely strange. Goldman's James Sheehan doubled his target from $400 to $900 while maintaining a Neutral rating — a target that was behind the tape before the ink dried. Wells Fargo lifted to $1,220 and Cantor Fitzgerald to $1,500, both maintaining Overweight. These follow a wave that started late May: Morgan Stanley to $1,050, Raymond James to $1,100, UBS to $1,625, Susquehanna to $1,750. Every single name on that list raised their target; not one downgraded. The consensus mean now prints at $811, still anchored by pre-rally targets that haven't been refreshed. The Street is unanimously bullish in direction but chaotically spread in conviction — a $900 gap between Goldman's floor and Susquehanna's ceiling is not a range, it is a confession that nobody has high confidence in where fair value sits. The bull case centres on HBM leadership, data centre SSD momentum, and AI-adjacent memory demand. Bears point to the cyclical nature of DRAM pricing, heavy capex commitments, and the risk that a supply response erodes the premium the market is currently paying.
Positioning in the lending market gives no support to the bear case. Share availability is essentially uncapped — well over 1,000% relative to short interest, meaning the lending pool is flush with supply. Borrowing costs have collapsed, falling 46% on the week to just 0.22%, the lowest level in the 30-day window and a fraction of where they were in early May when the stock was 700 points lower. Short interest is 3.4% of free float, and it edged up 8.7% on the week in share terms — a modest rebuild, not a conviction short. That combination of loose borrow and low cost tells a clear story: this is not a stock where bears are scrambling for access. The options market is more cautious. The put/call ratio has been running near 1.32 all week — above its 20-day average of 1.23 and close to the 52-week high of 1.37. A z-score of 1.25 confirms the reading is elevated but not extreme. Demand for downside protection is higher than usual, consistent with a stock that has moved violently in both directions recently, but the options signal looks more like hedging than directional conviction.
The CEO's fingerprints are visible in the ownership data. Sanjay Mehrotra sold approximately $9.5 million worth of stock on May 29 across multiple tranches, near prices between $944 and $971. The 90-day net insider figure is technically positive at roughly $31.9 million, but the recent-trades table is entirely composed of Mehrotra sell transactions. The sales carry a significance score of 2 — routine in framing — and the price levels suggest they were part of a pre-arranged plan rather than a discretionary call on valuation. Still, the cluster is notable: the CEO was actively selling at prices the stock has since fallen through.
Earnings are the next live event. Micron reports on June 24. The most recent prior earnings reaction — March 18 — produced a 3.8% single-day decline followed by a 17.2% five-day loss. That history matters in context: the stock was trading at meaningfully lower levels then, the memory cycle was at a different point, and the analyst community was not yet running targets above $1,000. The setup this time is different in degree but similar in structure — a stock that has run hard into the quarter, with options traders hedging and analysts still catching up to a price that moved faster than their models.
The question for June 24 is whether Micron's guidance on HBM allocation and DRAM pricing can justify a stock that, even after a 12% weekly pullback, has returned more than 150% year-to-date and trades above the majority of Street price targets.
See the live data behind this article on ORTEX.
Open MU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
